Sou Hu Cai Jing·2025-10-24 10:19Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces significant risks of forced delisting due to major violations of laws and regulations related to information disclosure and financial reporting [2]. Group 1: Stock Performance - As of October 24, 2025, *ST Wuzhong (600200) closed at 1.06 yuan, up 4.95% from the previous trading day, with a total market capitalization of 754 million yuan [1]. - The stock opened at 1.02 yuan, reached a high of 1.06 yuan, and a low of 1.01 yuan, with a trading volume of 68.282 million yuan and a turnover rate of 9.13% [1]. Group 2: Regulatory Issues - The company was investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, leading to a formal investigation initiated on February 26, 2025 [2]. - On July 13, 2025, the company received a notice of administrative penalty, indicating that it engaged in trade activities with subsidiaries and related companies that lacked commercial substance, resulting in inflated revenue, costs, and profits in annual reports from 2020 to 2023 [2]. - The stock has been subject to multiple delisting risks, including major violations, financial issues, and face value concerns, since July 14, 2025 [2]. Group 3: Financial Performance - The company reported a net profit of -44.4178 million yuan for the first half of 2025, showing a significant decline year-on-year [2]. - As of the end of 2023, non-operating funds occupied by related parties of the controlling shareholder amounted to 1.6926071 billion yuan, which remains unresolved [2]. - The financial report for the year 2024 received a disclaimer of opinion, triggering financial delisting risk warnings [2].